Liothyronine

Liothyronine sodium (LT3) is a synthetic form of triiodothyronine (T3), the biologically active thyroid hormone. Whereas levothyroxine (LT4) is a prohormone that requires peripheral conversion to T3 for its physiological effects, liothyronine is active as administered — it binds directly to thyroid hormone receptors without requiring enzymatic conversion. T3 has approximately 3–4 times the potency of T4 on a microgram-per-microgram basis and a substantially shorter elimination half-life (approximately 2.5 days versus 6–7 days for LT4), which produces a faster onset and faster offset of action and a tendency toward more pronounced swings in serum T3 concentrations over the dosing interval.¹

In healthy individuals with a functioning thyroid, T3 is produced both directly by the thyroid gland (approximately 20% of systemic T3) and by peripheral deiodination of T4 (approximately 80%). Some individuals with hypothyroidism on levothyroxine monotherapy continue to experience symptoms despite normal TSH levels, and impaired T4-to-T3 conversion has been proposed as a contributing mechanism in some of these patients — though this remains a topic of active clinical debate.

Liothyronine sodium is FDA-approved as replacement or supplemental therapy for:¹

• Hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This is the primary indication but liothyronine is not the standard first-line agent for routine hypothyroidism — levothyroxine is.
• Myxedema: Liothyronine's rapid onset makes it preferred over LT4 in some clinicians' practice for myxedema coma, although intravenous LT4 formulations are also available and used.
• Thyroid suppression testing: Liothyronine may be used diagnostically to suppress thyroid radioactive iodine uptake; its short half-life enables more rapid return to baseline than LT4.
• T3 preparation for thyroid cancer patients undergoing radioactive iodine scanning: Liothyronine allows a shorter period of hypothyroidism before scanning compared to LT4 withdrawal, though recombinant TSH (Thyrogen) has largely replaced this approach.

Off-label uses: Combination therapy with levothyroxine (LT4/LT3) for hypothyroidism in patients with persistent symptoms on LT4 monotherapy — a practice that is controversial. The American Thyroid Association's 2012 guidelines stated that evidence does not support LT4/LT3 combination therapy as superior to LT4 alone for most patients; more recent research has produced mixed results and the question remains under investigation. Some clinicians offer a trial of LT4/LT3 combination to patients with ongoing symptoms on LT4. Liothyronine has also been used off-label in euthyroid patients for depression augmentation; the FDA label explicitly warns against use for obesity or weight loss.¹

For hypothyroidism in adults:¹

• Starting dose: 5 mcg once daily (lower than most LT4 starting doses on a proportional basis, reflecting the greater potency per microgram of T3).
• Dose may be increased by 5–10 mcg every 1–2 weeks as clinically needed.
• For mild hypothyroidism: maintenance doses of 25 mcg daily are often sufficient.
• For combination use with LT4: small doses of liothyronine (typically 5–12.5 mcg, sometimes split into two daily doses) are added to a reduced LT4 dose. The appropriate conversion ratio and dosing protocol for combination therapy are not standardized.

The short half-life of liothyronine necessitates twice-daily dosing in some contexts to avoid pronounced T3 peaks and troughs over a 24-hour period.

Oral tablet. Intravenous formulations are available for clinical use in settings such as myxedema coma.

Store at controlled room temperature. Protect from light and moisture.¹

The principal clinical challenge with liothyronine is its pharmacokinetic profile. The short half-life produces peaks in serum T3 within 2–4 hours of dosing and returns toward baseline by 12–24 hours, creating pulsatile T3 exposure rather than the relatively stable levels produced by once-daily LT4.¹ This pharmacokinetic pattern is the primary reason most thyroid society guidelines recommend against liothyronine monotherapy as routine replacement for hypothyroidism, and why combination LT4/LT3 therapy has not achieved consensus endorsement despite persistent patient interest.

Additional considerations:¹

• Cardiac risk: The pulsatile T3 peaks associated with liothyronine dosing may pose greater risk in older patients and those with pre-existing cardiac disease or arrhythmia; more caution is warranted in these populations than with LT4.
• Signs of overtreatment: Because liothyronine is more potent and faster-acting than LT4, the signs of overreplacement (palpitations, tremor, heat intolerance, anxiety, sweating, weight loss) may manifest more acutely with dosing errors or escalation.
• Laboratory monitoring: TSH is used for monitoring; however, TSH suppression with liothyronine monotherapy can occur even when the patient is not clinically hyperthyroid, because the T3 peak suppresses pituitary TSH before equilibrium is reached. Free T3 levels may be a useful adjunct for monitoring in some contexts.
• Weight loss use is not supported: As with levothyroxine, the FDA label explicitly states that liothyronine at physiological replacement doses is ineffective for weight reduction in euthyroid patients, and that supraphysiological doses carry serious toxicity risk.
• Drug interactions: Liothyronine can increase the sensitivity of anticoagulant therapy (warfarin), and cholestyramine impairs its absorption. Estrogens affect thyroid-binding globulin and may alter T3 levels in patients also using estrogen-containing products.